University Hospital of North Norway
Tromsø, 9038, Norway
NCT Number: NCT01103427
The purpose of the study is to investigate the effectiveness of a smoking cessation intervention delivered through a technological web based platform (www.slutta.no) with or without a supportive SMS function.
Looking for future studies?
Notify Me16 year and older
All sexes
Interventional
Not applicable
Tromsø, 9038, Norway
The study has two arms and are conducted in Norwegian. Users who registered with a new username on www.slutta.no, after study start May 12th 2010 and before November 1st 2012, are eligible. All phases of the trial, from randomization and informed consent procedures to data collection, are automated and conducted online. The following inclusion criteria are used: age 16 years or older, access to a mobile phone with a Norwegian phone number and they must submit an informed consent form.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(all arms):
Exclusion criteria
Those in the "active comparator arm" will benefit from automated coaching by e-mails with advice, information and support for smoking cessation. These e-mails will be adapted to their personal profile.
Other names: slutta.no
Those in the experimental SMS based coaching arm will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
Other names: slutta.no
Those in the experimental SMS based coaching arm- UNN recruited - will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
Other names: slutta.no/unn
Those in the experimental SMS based craving/panic function arm - will in addition to the automated coaching by SMS have a panic/craving SMS function. Thus by sending a SMS they will receive instant advise and support for smoking cessation by SMS.
Other names: slutta.no/unn
Time frame: 30 months after inclusion
The investigators will compare the percentage of smokers who successfully quit. Point prevalence abstinence will be measured (not smoking, event a puff, in the week preceding the questioning).
Time frame: 30 months after inclusion
Number of visits to the website, time logged in, used elements of the website and adherence to the program will be measured utilizing the registrations on the server.
Time frame: 30 months after inclusion
The 4 questionnaires comprise questions regarding satisfaction with website or text messages for the different arms depending om which device they have been utilizing.
Time frame: 6 months after selfreported smoking cessation date
Comparison between the four arms regarding self-reported 28 days continuous smoking abstinence through questionnaire
Time frame: 6 months after selfreported smoking cessation date
Involvement in any vehicle crashes (this is the only rare adverse health effects of using a mobile phone)during the 6 months after selfreported smoking cessation date.
University of Tromso
Other
Mobile Text Messaging as an Adjunct Function to an Internet-based Smoking Cessation Intervention Implemented in the General Population and in a Health Care Setting
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03206619
Behavior, Habits
Seville, Spain
View Trial DetailsNCT05490251
Behavior, Fractures, Bone
Los Angeles, California, United States
View Trial DetailsNCT04532970
Behavior, Blood-Borne Infections
Gaborone, Botswana
View Trial DetailsNCT04505371
Behavior, Blood-Borne Infections
Seattle, Washington, United States
View Trial Details